Latest Repros Therapeutics Inc. Stories

2008-11-10 18:00:05

Repros Therapeutics Inc. (NasdaqGM:RPRX) announced today that it has filed a Form S-3 shelf registration statement with the Securities and Exchange Commission for up to 6,282,052 shares of common stock. The Company has filed this shelf registration statement for two reasons. First, the Company is required to register the resale of the shares issuable upon exercise of option rights granted to certain investors in its recently completed direct registered offering of 2.4 million shares of...

2008-10-29 18:00:07

Repros Therapeutics Inc. (NasdaqGM:RPRX) announced today that the Company's President and CEO, Joseph Podolski, will present a corporate overview on Monday, November 3, 2008, at 2:00 p.m. Eastern Time during the Oppenheimer 19th Annual Healthcare Conference. Mr. Podolski will also present on Tuesday, November 11, 2008, at 10:20 a.m. Eastern Time during the Rodman & Renshaw 10th Annual Healthcare Conference. And on December 2, 2008, at 8:00 a.m. Eastern Time, Mr. Podolski will present from...

2008-10-02 21:00:23

Repros Therapeutics Inc. (NasdaqGM:RPRX) today announces that it has consummated its previously announced sale of an aggregate of 2.4 million shares of its common stock resulting in net proceeds to the Company of approximately $15.5 million after deduction of estimated offering expenses. Additionally, the Company amended the Standstill Agreement with Efficacy Capital LTD to permit Efficacy Capital to own up to 40% of the Company's outstanding shares of stock and to permit Efficacy...

2008-09-29 09:00:58

Repros Therapeutics Inc. (NasdaqGM:RPRX) today announces that it has entered into definitive agreements to sell an aggregate of 2.4 million shares of its common stock at a purchase price of $6.50 per share for an aggregate $15.6 million financing under its previously announced shelf registration statement. The Company intends to close all of the sales on Friday, October 3, 2008. As of September 29, 2008, excluding any proceeds from this offering, Repros had cash and cash equivalents of...

2008-08-21 06:00:19

Repros Therapeutics Inc. (NasdaqGM:RPRX) today released the evaluation of the microscopic assessment of tissues from a six-month mouse study conducted to satisfy a portion of the FDA mandated two-species trials to demonstrate the lack of carcinogenic potential for new chemical entities. In this positive and negative controlled study, Proellex showed no microscopic evidence for tumor induction as compared to both controls. Proellex was tested at 10, 40 and 100 times the human dose in this...

Word of the Day
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'